CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 752 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01155570
NCT01155570N/ACompleted
CompareCT.gov

Special Investigation (All Cases Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis)

AbbVie (prior sponsor, Abbott)·observational·Posted Jul 2, 2010·Updated Oct 8, 2013

In Brief

An observational study for Psoriasis. Completed, enrolled 752 participants across 634 sites.

Detailed Summary

The survey will be conducted with regard to the following aspects of treatment with Humira (adalimumab) in patients with psoriasis vulgaris and psoriatic arthritis receiving this drug: * unknown adverse drug reactions, especially clinically significant adverse reactions * incidence and conditions of occurrence of adverse reactions in the clinical setting * factors that may affect the safety and effectiveness of Humira.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2010
Enrollment StartFeb 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16 years ago